Doctor concerned with health care law

Breaking news and expert analysis on legal and compliance issues

[Back To Home][Back To Archives]

From Health Law Daily, August 20, 2018

Manufacturing quotas for opioids proposed at 10% reduction for 2019

By Patricia K. Ruiz, J.D.

The Drug Enforcement Agency (DEA) proposed reducing manufacturing quotas by an average of 10 percent for the six most frequently misused opioids. The reduced quotas come as a result of the Trump Administration’s "Safe Prescribing Plan," which seeks to cut nationwide opioid prescription fills by one-third in three years (Notice, 83 FR 42164, August 20, 2018).

Quotas for 2019. For 2019, the DEA proposed to reduce more commonly prescribed schedule II opioids, including oxycodone, hydrocodone, oxymorphone, hydromorphone, morphine, and fentanyl. The quotas detailed in the DEA’s proposal represent the quantities of the specified chemicals to be manufactured in the U.S. during the year to provide for the estimated medical, scientific, research, and industrial needs of the U.S.; lawful export requirements; and the establishment and maintenance of reserved stocks. The quotas include imports of ephedrine, pseudoephedrine, and phenylpropanolamine but not imports of controlled substances for use in industrial processes. The DEA will accept comments on its proposal through September 19, 2019.

Setting of annual quotas. Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. § 826) requires the Attorney General (AG) to establish aggregate production quotas for each basic class of controlled substances listed in schedules I and II and for ephedrine, pseudoephedrine, and phenylpropanolamine. The AG delegated the function to the DEA. In setting annual aggregate production quotas, the DEA considers data from sources including FDA estimates of legitimate need, estimates of retail consumption based on prescriptions dispensed, manufactures’ disposition history and forecasts, data from the DEA’s system for tracking controlled substance transactions, and past quota histories.

In 2018, the DEA issued a final rule (83 FR 32784) amending its regulations to improve its ability when setting annual opioid production limits to consider the likelihood of whether a drug can be diverted for abuse, as well as any relevant information obtained from HHS and from the states. The 2019 aggregate quotas proposed were determined with consideration of these factors.

MainStory: TopStory Notices CMSNews FDCActNews ControlledNews DrugBiologicNews FraudNews PrescriptionDrugNews SafetyNews FedTracker LifeSciences HealthCare

Back to Top

Health Law Daily

Introducing Wolters Kluwer Health Law Daily — a daily reporting service created by attorneys, for attorneys — providing same-day coverage of breaking news, court decisions, legislation, and regulatory activity.

A complete daily report of the news that affects your world

  • View full summaries of federal and state court decisions.
  • Access full text of legislative and regulatory developments.
  • Customize your daily email by topic and/or jurisdiction.
  • Search archives for stories of interest.

Not just news — the right news

  • Get expert analysis written by subject matter specialists—created by attorneys for attorneys.
  • Track law firms and organizations in the headlines with our new “Who’s in the News” feature.
  • Promote your firm with our new reprint policy.

24/7 access for a 24/7 world

  • Forward information with special copyright permissions, encouraging collaboration between counsel and colleagues.
  • Save time with mobile apps for your BlackBerry, iPhone, iPad, Android, or Kindle.
  • Access all links from any mobile device without being prompted for user name and password.